Tag Archives: immunotherapy

New Mesothelioma Immunotherapy Trial Now Underway at Baylor

mesothelioma immunotherapy trial

Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy.  The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma.  How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor »

Mesothelioma Immunotherapy Drug Keytruda Gets a Boost from Opdivo Study

mesothelioma immunotherapy drug

The company that makes a promising new mesothelioma immunotherapy drug got a boost from a competitor’s study this week.  The makers of the lung cancer drug Opdivo have released some disappointing results from their latest lung cancer trial. The findings present another setback for Bristol-Myers Squibb.  But they are good news for Merck, the maker of the mesothelioma immunotherapy drug Keytruda. In the wake of the publication, Merck’s stocks rose while Bristol-Myers’ dropped.  How Opdivo Works Opdivo is the brand name for nivolumab. It is a monoclonal antibody that blocks PD-1. PD-1 is a cell surface protein expressed by some lung cancer and mesothelioma tumors. An Australian study estimated that more than 72 percent of mesothelioma patients overexpress PD-1. Opdivo … Continue reading Mesothelioma Immunotherapy Drug Keytruda Gets a Boost from Opdivo Study »

Immunotherapy Vaccine for Mesothelioma Shows Promise in Combination Treatment

immunotherapy vaccine for mesothelioma

A bacteria-based immunotherapy vaccine for mesothelioma may improve the odds of surviving the disease by boosting the effects of chemotherapy.  That is the word from the latest clinical trial of CRS-207 headed by researchers at the National Cancer Institute. Thirty-five inoperable patients received the immunotherapy vaccine for mesothelioma along with standard mesothelioma chemotherapy. Eighty-nine percent of them experienced either a full or partial response to the treatment combination.  CRS-207 Immunotherapy Vaccine for Mesothelioma CRS-207 is based on a modified version of Listeria monocytogenes. The bacterium is best known for causing the food borne illness Listeriosis. In CRS-207, the bacteria has been changed so it cannot make patients sick. The immunotherapy vaccine for mesothelioma uses the bacteria to trigger a powerful … Continue reading Immunotherapy Vaccine for Mesothelioma Shows Promise in Combination Treatment »

Palliative Radiotherapy for Mesothelioma Produces “Substantial Treatment Response”

palliative radiotherapy for mesothelioma

Doctors in Pennsylvania may have found a way to boost the effectiveness of palliative radiotherapy for pleural mesothelioma. Palliative radiotherapy is used to help with mesothelioma symptoms. It uses lower doses of radiation. Doctors do not expect to treat mesothelioma with palliative radiotherapy. But researchers at the University of Pennsylvania think it could also be a treatment. They combined palliative radiotherapy with a special kind of gene therapy. The gene therapy affects the immune system. They say the combination produced a “substantial treatment response” in a man with mesothelioma. Immuno-gene Therapy and Palliative Radiotherapy Immuno-gene therapy uses genes to stimulate the immune system against cancer. In the new Pennsylvania case study, a 67-year-old man with mesothelioma received immuno-gene therapy. Doctors … Continue reading Palliative Radiotherapy for Mesothelioma Produces “Substantial Treatment Response” »

Chemoimmunotherapy Called “Next Frontier” for Mesothelioma Cancer

mesothelioma cancer treatment

Mesothelioma researchers in Australia are calling the combination of chemotherapy and immunotherapy the “next frontier” in the treatment of mesothelioma cancer. In a study published in the journal Expert Opinions in Biological Therapy, the researchers reviewed past clinical trials on mesothelioma immunotherapy. They focused on studies published between 2016 and 2018. Their goal was to get a clearer picture of just how effective these drugs are and how they might be used in combination with other treatments. Chemotherapy for Mesothelioma Cancer Currently, immunotherapy is not the primary treatment for mesothelioma cancer. Instead, most patients have chemotherapy, which is considered the gold standard treatment. For the past 15 years, Alimta has been the main chemotherapy drug for people with malignant mesothelioma. … Continue reading Chemoimmunotherapy Called “Next Frontier” for Mesothelioma Cancer »

Combination Mesothelioma Therapy Begins Pivotal Trial

mesothelioma treatment combination

A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial »

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

mesothelioma clinical trial of dendritic cells

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy »

PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma

mesothelioma immunotherapy response

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma »

Predicting Thyroid Disease After Immunotherapy for Mesothelioma

thyroid disease after imminotherapy

Researchers in Italy say it is possible to predict which mesothelioma patients are likely to develop thyroid disease after immunotherapy. They are advising their colleagues to use the technique for better management of malignant mesothelioma. Immune checkpoint inhibitors like Keytruda are improving the outlook for people with asbestos cancer. But immunotherapy is not without risk. Certain people are prone to develop thyroid disease after immunotherapy. If doctors know ahead of time which mesothelioma patients are at risk, they can be better prepared to manage problems later.   Immune Checkpoint Inhibitors and Thyroid Disease after Immunotherapy Pleural mesothelioma is extremely difficult to treat. Immune checkpoint inhibitors have given many mesothelioma patients new hope. Recent studies suggest that some of these drugs … Continue reading Predicting Thyroid Disease After Immunotherapy for Mesothelioma »

Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy

X-ray showing location of intrapleural immunotherapy

New metadata suggests that intrapleural immunotherapy is a powerful, targeted way to treat malignant pleural mesothelioma.   Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat. Now, a new study suggests that delivering immunotherapy treatments directly into the pleural space where mesothelioma tumors form may help these drugs work even better. What is Intrapleural Immunotherapy? Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery. Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment. Intrapleural immunotherapy is a more targeted way to deliver these cancer-fighting messengers. It does … Continue reading Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy »